Library samples containing 2,5-disubstituted oxadiazoles were identified as potent hits in a high throughput screen (HTS) of the NIH Molecular Libraries Small Molecule Repository (MLSMR) directed at discovering inhibitors of cathepsin L. However, when synthesized in pure form, the putative actives were found to be devoid of biological activity. Analyses by LC-MS of original library samples indicated the presence of a number of impurities, in addition to the oxadiazoles. Synthesis and bioassay of the probable impurities led to the identification of a thiocarbazate that likely originated via ring opening of the oxadiazole. Previously unknown, thiocarbazates (-)-11 and (-)-12 were independently synthesized as single enantiomers and found to inhibit cathepsin 20 L in the low nanomolar range. Abstract-Library samples containing 2,5-disubstituted oxadiazoles were identified as potent hits in a high throughput screen (HTS) of the NIH Molecular Libraries Small Molecule Repository (MLSMR) directed at discovering inhibitors of cathepsin L. However, when synthesized in pure form, the putative actives were found to be devoid of biological activity. Analyses by LC-MS of original library samples indicated the presence of a number of impurities, in addition to the oxadiazoles. Synthesis and bioassay of the probable impurities led to the identification of a thiocarbazate that likely originated via ring opening of the oxadiazole. Previously unknown, thiocarbazates (À)-11 and (À)-12 were independently synthesized as single enantiomers and found to inhibit cathepsin 20
The cathepsins comprise a family of lysosomal protease enzymes whose primary function (i.e., protein degradation) plays a critical role in normal cellular homeostasis. 1 Overexpression of cathepsin L and/or abnormal activity has been implicated in a number of disease states. 2 For example, cathepsin L is responsible for bone 30 resorption through degradation of collagen type I; this disregulation is believed to lead to osteo-and rheumatoid arthritis. 3 In addition, several infective organisms, such as SARS and Ebola viruses, utilize cathepsin L-like proteins for replication in human cells. 4 The large number of disease states associated with cathepsin L calls for an understanding of the biological function. 2 Recently, the Penn Center for Molecular Discovery (PCMD), 5 completed a high throughput screening (HTS) campaign of the NIH Molecular Libraries Small
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Molecule Repository (MLSMR) to identify inhibitors of members of the papain-like cysteine protease family, including cathepsins B, L, and S. 6 In this letter, we detail our continuing efforts to create a comprehensive, publicly available profile of small-molecule inhibitors of the cysteine protease class, and herein describe the identification of a novel class of potent cathepsin L inhibitors.
Previously reported inhibitors of cathepsin L include the peptides, leupeptin and aprotinin, and the fluoromethyl 50 ketone, Z-LLL-FMK. 3, 7 The few known, potent smallmolecule inhibitors are either peptidic and therefore likely to suffer from physiological instability and poor permeability, or are non-selective for cathepsin L. 3, 8, 9 The identification of potent, selective, stable, and cell permeable small-molecule inhibitors would therefore be a valuable tool to interrogate cathepsin L and cathepsin L-like function, as well as to provide potential starting points for drug discovery and development. [10] [11] [12] [13] [14] [15] Initial HTS results of our cathepsin L screen indicated 60 that several structurally related oxadiazoles exhibited potent inhibitory activity (Table 1) . [16] [17] [18] The most potent hit, cataloged in the MLSMR as disubstituted oxadiazole 1, exhibited an IC 50 of 0.13 lM.
17
Wells containing related analogs (2-5), differing only
in the amide nitrogen substitution, displayed a range of activities (IC 50 = 0.16-0.51 lM), suggesting a nascent structure activity relationship. As is our practice, library samples containing the putative active oxadiazoles were evaluated for both purity and integrity by LC-MS anal-
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ysis. This analysis indicated that the primary constituent of each sample was indeed the expected oxadiazole, in up to 60% purity, however numerous impurities were also present. To confirm the biological activity attributed to 1, a synthetic sequence was developed to generate the oxadiazoles in pure form.
Although little literature precedence exists for the construction of compounds such as 1, we realized that modification of the Woodward-Confalone 19 approach to aamino acid substituted oxadiazolethiones could provide Initial attempts to remove the Boc-group utilizing HCl in dioxane (4 N) or HCl in water (6 N) were compromised by the poor solubility of (+)-8. However, small quantities of the HCl salt of 1 could be obtained by 100 treatment with 6 N HCl over 45 min. Upon LC-MS analysis of synthetic 1, we recognized that the impurities formed during the acid-promoted Boc-deprotection step were identical to those found in the library screening samples (vide infra). Optimal conditions to remove the Boc-group were eventually developed. Specifically, treatment of (+)-8 with 25% water in TFA for 15 min, followed in turn by adjustment of the pH to 8.0 with NaHCO 3 and aqueous extraction with methylene chloride-furnished the free-base of 1 in 89% yield and 99% 110 after column chromatography. In the end, oxadiazole 1 was prepared on gram scale from L L-Boc-Trp-OH; the overall yield was 76%. 
U N C O R R E C T E D P R O O F
To our surprise, the free-base of 1 was found to be completely devoid of activity when assayed against cathepsin L. 18 This result suggested that an impurity present in the original library sample was responsible for the observed activity. Based on LC-MS analyses of the biologically active samples, we hypothesized that the active component was likely the ring-opened product 10, formed via 120 acid-promoted addition of H 2 O to (+)-8 ( Fig. 1) .
The presence of a molecular [M+1] ion equal to 440 amu in the LC-MS analysis of impure samples was consistent with the presence of 10, thereby providing strong support for the hypothesis.
Thiocarbazates such as 10 have not been described previously in the literature. However, these compounds do bear structural resemblance to aza-peptides [22] [23] [24] (e.g., A; Fig. 2) , 25 examples, of which have been reported to exhibit cysteine protease inhibitory activity through a 130 mechanism involving attack by the active site cysteine on the carbamate carbonyl. 26 To test the hypothesis that 10 was indeed the active species, we devised an expedient synthesis of this structural class. We envisioned that introduction of the C2 carbonyl unit of 10 could be achieved via chemistry in parallel to that used to prepare 1, beginning with hydrazide (+)-6. We began the synthesis by converting tryptophan hydrazide (+)-6 to an intermediate thiosemicarbazide (not shown) employing carbonyl sulfide (S@C@O) gas 140 dissolved in ethanol (Scheme 2). 27 The intermediate thiosemicarbazide did not precipitate from solution, therefore 2-bromo-N-(2-ethyl-phenyl)-acetamide 21 (9) was added to the reaction flask to generate thiocarbazate (À)-11.
28 Pleasingly, the yield for the two-step, one-flask operation was 62%. Deprotection of (À)-11, employing our previously developed condi- 
tions (25% water in TFA), generated the free-base (À)-12 in 98% yield with >95% purity. This three-step sequence permitted construction of (À)-12 on gram 150 scale, starting from L L-Boc-Trp-OH; the overall yield was 58%.
As anticipated, both (À)-11(S) and (À)-12(S) exhibited potent inhibitory activity against cathepsin L with IC 50 values of 56 nM and 133 nM, respectively. 29 The Renantiomer, (+)-11(R), 30 was only modestly active against cathepsin L (IC 50 = 34 lM). 29 Some variability in IC 50 values determined for (À)-12 prompted us to explore the stability of both (À)-11 and (À)-12 in solvents relevant to the bioassay. While (À)-11 was found to be 160 completely stable in DMSO, as well as in the buffer employed in the Cathepsin L assay [e.g., NaOAc (20 mM), pH 5.5; EDTA (1 mM); cysteine (5 mM)], the free-base (À)-12 proved unstable in DMSO, generating decomposition products 13, 14, and 15 after only 1 h at room temperature (Fig. 3) .
Presumably 13-15 are formed from (À)-12 via intramolecular attack of the primary amine on the C2 thiocarbazate moiety, and release of 13. These products, prepared either via synthesis (13 and 14) or by HPLC 170 purification of decomposed material (15) , were assayed for cathepsin L activity and found to be inactive. Due to the instability of (À)-12 under the assay conditions, IC 50 values vary somewhat, rendering interpretation of the bioassay data difficult. We are, however, confident in the accuracy of the bioassay results for (À)-11, as this compound is stable under all conditions evaluated. Thus, future efforts will be focused on the more stable thiocarbazate (À)-11 and related congeners.
As most cysteine protease inhibitors contain an electro-180 philic 'warhead,' and work through a mechanism involving reaction with the active site cysteine, 7,26 we strongly believe these novel thiocarbazates behave similarly, and are active by virtue of their electrophilic carbonyl moiety. The formation of 15 supports this mechanism and is indicative of the electrophilicity of the C2 carbonyl moiety. Reactivity at the anilide carbonyl is also a possibility and cannot be ruled out. However, we observe no evidence of side-products resulting from reaction at this position (cf. Fig. 3) . A complete biochemical charac-190 terization of this novel chemotype is underway. 31 In summary, samples from the NIH MLSMR revealed promising cathepsin L inhibitory activity attributed to a series of 2,5-disubstituted oxadiazoles (1) (2) (3) (4) (5) . Analytical analyses (LC-MS) of the library samples, however, indicated numerous impurities, thus requiring the development of an efficient synthesis for the putative active 2,5-disubstituted oxadiazoles. Synthetic samples of pure 2,5-disubstituted oxadiazoles were found to be completely devoid of cathepsin L inhibitory activity.
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Careful LC-MS investigation of both the library and synthetic samples revealed a thiocarbazate to be the active component. Bioassay of the synthetic thiocarbazates confirmed the hypothesis: (À)-11 and (À)-12 display potent inhibitory activity against cathepsin L, with IC 50 values of 56 nM and 133 nM, respectively, however instability of (À)-12 was also noted. The design, syntheses, and biological evaluation of analogs of the highly potent lead thiocarbazate class are now ongoing in our laboratories, and will be reported in 210 due course.
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